$23.78
Value $1.1B
RAPP and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$23.78
Value $1.1B
$688.38
Value $256B
Rapport Therapeutics (RAPP) has a market value of $1.1B and Thermo Fisher Scientific (TMO) $256B. Over the last year, with dividends, RAPP moved -2.4% and TMO +19.4%. Dividend yield: RAPP none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
RAPP$1.1B
TMO$256B
TMO is 225 times RAPP
Revenue, 12 months
RAPP–
TMO$47.4B
Net income, 12 months
RAPP-$150M
TMO$7.1B
Operating margin
RAPP–
TMO17.9%
ROIC
RAPP-20.4%
TMO8.2%
28.6 points apart
P/E
RAPP–
TMO36.2
Dividend yield
RAPP0.0%
TMO0.3%
0.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
RAPP-2.4%
TMO+19.4%
| Period | RAPPWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -2.4%Price -2.4% | +19.4%Price +19.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
RAPPRapport TherapeuticsTMOThermo Fisher Scientific
| Price | $23.78 | $688.38 |
|---|---|---|
| Market value | $1.1B | $256B |
| Enterprise value (EV) | $742M | $291B |
| P/E | – | 36.2 |
| P/E, 5-year median | – | 32.7 |
| P/B | 2.9 | 4.7 |
| EV/EBIT | – | 34.4 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | – | $47.4B |
|---|---|---|
| Net income, 12 months | -$150M | $7.1B |
| Free cash flow, 12 months | -$121M | $7.6B |
| Earnings per share, 12 months | -$3.16 | $18.96 |
| Revenue growth, year on year | – | 3.9% |
| Revenue growth a year, past | – | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | – | 17.9% |
| Net margin | – | 14.9% |
| ROIC | -20.4% | 8.2% |
| ROE | -33.0% | 13.4% |
| Cash | $395M | $6.1B |
|---|---|---|
| Total debt | $9.4M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | 0.0% | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($256B) is about 225.0 times Rapport Therapeutics ($1.1B), at today's prices.
Since November 14, 2025, RAPP's price moved -2.4% and TMO's +19.0%. With dividends: RAPP -2.4% (-2.4% a year), TMO +19.4% (+19.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Rapport Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.